Found: 16
Select item for more details and to access through your institution.
Body weight loss with oral semaglutide is mediated predominantly by effects other than gastrointestinal adverse events in patients with type 2 diabetes: A post hoc analysis.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1130, doi. 10.1111/dom.14957
- By:
- Publication type:
- Article
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials.
- Published in:
- Diabetes, Obesity & Metabolism, 2021, v. 23, n. 12, p. 2752, doi. 10.1111/dom.14532
- By:
- Publication type:
- Article
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 5, p. 779, doi. 10.1111/dom.13954
- By:
- Publication type:
- Article
A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 5, p. 873, doi. 10.1111/dom.13957
- By:
- Publication type:
- Article
The co‐formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta‐analysis of phase III studies in patients with type 2 diabetes
- Published in:
- Diabetes, Obesity & Metabolism, 2018, v. 20, n. 7, p. 1585, doi. 10.1111/dom.13261
- By:
- Publication type:
- Article
Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
- Published in:
- Journal of Diabetes Investigation, 2016, v. 7, n. 4, p. 574, doi. 10.1111/jdi.12461
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients.
- Published in:
- Journal of Diabetes Investigation, 2016, v. 7, n. 2, p. 270, doi. 10.1111/jdi.12399
- By:
- Publication type:
- Article
The rate of hyperglycemia and ketosis with insulin degludec‐based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trials.
- Published in:
- Pediatric Diabetes, 2019, v. 20, n. 3, p. 314, doi. 10.1111/pedi.12821
- By:
- Publication type:
- Article
Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes.
- Published in:
- Pediatric Diabetes, 2016, v. 17, n. 8, p. 642, doi. 10.1111/pedi.12358
- By:
- Publication type:
- Article
Greater Combined Reductions of HbA<sub>1c</sub> ≥ 1.0% and Body Weight Loss ≥ 5.0% or ≥ 10.0% with Orally Administered Semaglutide Versus Comparators.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 8, p. 1415, doi. 10.1007/s13300-023-01413-5
- By:
- Publication type:
- Article
Commentary to "Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec" by Kawaguchi et al. Diabetes Therapy 2019.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 2, p. 561, doi. 10.1007/s13300-019-00755-3
- By:
- Publication type:
- Article
IDegLira Improves Glycemic Control in Japanese Patients with Uncontrolled Type 2 Diabetes on Premixed Insulin Therapy.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 1, p. 331, doi. 10.1007/s13300-019-00730-y
- By:
- Publication type:
- Article
Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
668-P: Body Weight Loss with Oral Semaglutide Is Predominantly Mediated by Effects Other than Gastrointestinal Adverse Events.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-668-P
- By:
- Publication type:
- Article
675-P: Effects of Liraglutide in T1D by Baseline Anthropometrics in ADJUNCT One and Two.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-675-P
- By:
- Publication type:
- Article
663-P: Achievement of Near-Normal HbA1c with Early Initiation of Oral Semaglutide: An Exploratory Subgroup Analysis of PIONEER 1.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-663-P
- By:
- Publication type:
- Article